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Abstract
Background: Osteoporosis is frequently observed in postmenopausal women. Evidence indicates that the role of genetic factors is
significant in osteoporosis. This study aimed to inspect the potential association between His 447 His polymorphism of PPARγ gene
and bone mineral density (BMD) and serum lipid profiles in postmenopausal women suffering from osteoporosis compared to the
healthy controls.
Methods: The study was conducted on 224 postmenopausal women including 107 osteoporosis patients (age: 61.03± 4.54 years)
and 117 healthy controls (age: 55.73± 2.08 years). Blood samples were analyzed for polymorphism of PPARγ gene using polymerase
chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods. Multivariate analysis was used to investigate
the relationship between the risk of osteoporosis and PPARγ gene polymorphisms.
Results: Serum low density lipoprotein (LDL) and total cholesterol (TC) levels were significantly different between the osteoporosis
group and the control group (P < 0.001). After adjustment for factors such as TC and LDL, logistic regression analysis showed that
the risk of osteoporosis was not significantly higher in carriers of homozygous wild-type genotype than carriers of the rare alleles
(P = 0.99, odds ratio = 0.997, 95% confidence interval = 0.52 - 1.91).
Conclusions: This study suggests that His 447 His polymorphism of PPARγ gene does not play the role of an independent factor in
BMD and osteoporosis in postmenopausal women.
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1. Background
Osteoporosis is the most common metabolic bone dis-
ease that can lead to increase of fragility of the bone tis-
sue (1, 2). The disease is more common in women than
men because they have a smaller bone mass and, during
post menopause, they produce less sex steroid hormones,
which decreases the body’s ability to retain calcium in the
bones (2). Previous studied show that osteoporosis affects
up to 50% of Iranian men and women over 50 years (3). Os-
teoporosis is characterized by reduced bone mineral den-
sity (BMD) and loss of bone microstructure (4). The best
way to measure BMD is to use dual energy X-ray absorp-
tiometry (DXA) (4). In previous years, studies have pro-
posed genetic factors as a major cause of BMD regulation
(2, 5). Peroxisome proliferator-activated receptor (PPAR)-
γ belongs to the nuclear hormone receptor family, which
is predominantly expressed in the adipose tissue, and also
plays an important role in the bone micro environment
(6). In addition, PPAR-γ activation seems to have regula-
tory effects on bone metabolism through regulating their
differentiation or activation into osteoclasts (7-9). How-
ever, evidence on whether the activation of PPAR-γ may af-
fect bone metabolism through the activation or inhibition
or cell lineages is not enough for conclusion. On the other
hand, PPARγ gene is located on short arm chromosome
3 (3p25) in human and is composed of 9 exons (10). Sev-
eral single nucleotide polymorphisms (SNP) have been de-
tected in PPARγ in human. The His 447 His polymorphism
(rs3856806) is known as C→T substitution in exon 6. The
His 447 His polymorphism is the most frequently found ge-
netic variant of PPARγ that has also been known as gender-
specific genetic modulator of metabolic homeostasis (11).
The less common T allele of the silent His 447 His poly-
morphism has been associated with low PPAR activity and
decreased ovarian androgen biosynthesis (12). Ogawa et
al. showed that there is a significant association between
His 447 His polymorphism of PPARγ gene and BMD in
postmenopausal Japanese women (13). Also, a previous
polymorphism study performed among Korean women
showed a significant relationship between this polymor-
phism and serum osteoprotegerin (OPG) level, as a key in-
hibitor of osteoclastogenesis (14). Since genetic variations
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could be of potential relevance to osteoporosis in post-
menopausal women, for the first time, we investigated in
this study the influence of PPARγ gene polymorphism on
osteoporosis in Iranian postmenopausal women.
2. Methods
2.1. Subjects
This case-control study was conducted on 224 post-
menopausal women who referred to the Bu-Ali hospital
of Qazvin, between January 2013 and February 2015. The
study was approved by the ethics committee of Qazvin
University of Medical Sciences, Qazvin, Iran. A total of
107 women with osteoporosis (case group) with the mean
age of 61.03± 4.54 years and 117 healthy postmenopausal
women (control group) with the mean age of 55.73± 2.08
years were selected. The women in the two groups were
carefully matched for BMI. None of the participants were
on special diet, none were cigarette smokers, and none
were alcohol consumers. Women were excluded from the
study if they had self-reported fracture history, known dys-
lipidemia, premature menopause, and systemic disease
such as thyroid dysfunction, diabetes mellitus, parathy-
roid disease, liver disease, and renal failure that might af-
fect bone metabolism or trace elements status. None of
the subjects had received hormone replacement therapy
and anabolic steroids, bisphosphonates, calcitonin, lipid-
lowering drugs, calcium and vitamin D supplements dur-
ing the six months preceding the onset of the study. All of
the participants completed a questionnaire including de-
mographic characteristic such as age, BMI, nutritional sta-
tus, previous fracture, and use of medicine.
2.2. BMD Measurements
BMD (g/cm2) was measured in the femur neck and lum-
bar spine 1-4 (L1-4) by DXA QDR
2000 (Hologic, Bedford, MA, USA). The coefficient of
variability values of DXA measurements was 1.0% for lum-
bar spine vertebra and 1.2% for femoral neck (14). Sub-
jects with spine or femur neck BMD 2.5 standard deviations
(SD) below a reference range (T score≤ 2.5) were accepted
as having postmenopausal osteoporosis (15). The con-
trol group (non-postmenopausal osteoporosis) consisted
of women with a T score≥ 1.5 on these sites.
2.3. Lipid Profile and Serum Parameters Analysis
Total cholesterol (TC), HDL-C, and triglyceride (TG)
were determined by standard enzymatic methods. LDL-C
was calculated by Friedewald formula: LDL-C = TC-(HDL-
C + TG/5) (16). Serum total calcium (normal range 8.5 -
10.5 mg/dL) was measured by using a colorimetric assay
while serum vitamin D was determined using the Enzyme-
Linked Immunosorbent Assay (ELISA) method (Alpco Diag-
nostics, Windham, United States).
2.4. Genotyping
Genetic analyses were performed on genomic DNA
isolated from peripheral blood leukocytes by standard
methods. A 181 bp sequence of the PPARγ gene was am-
plified by polymerase chain reaction (PCR) in a DNA
thermal cycle (ABI, Veriti, USA) by using oligonucleotide
primers 5’CCAGAAAATGACAGACCTCAGACA-3’ F, and 5’-
CAGAATAGTGCAACTGGAAGAAGG-3’ R.
The PCR condition was 95°C for 5 minutes, 35°C cycles
of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30
seconds, followed by 72°C for 7 minutes (17). Restriction of
the PCR product with the PmlI enzyme generates fragment
of 142/39 bp in rare homozygotes, 181/142/39 bp in heterozy-
gotes, and 181 bp in common homozygotes. Samples were
electrophoresed on 3% agarose gel and stained with ethid-
ium bromide.
2.5. Statistical Analysis
Values were presented as mean ± SD, and statistical
significance was defined as P values less than 0.05. Statis-
tically significant differences in mean measurements be-
tween different parameters were performed using t-test.
Correlation analysis between variables was performed by
calculating Pearson’s correlation coefficients. All analyses
were carried out using statistical software package, SPSS, V
11.0, for windows (Chicago, IL, USA).
3. Results
Demographic data and clinical characteristics are
shown in Table 1. Women with postmenopausal osteoporo-
sis had significantly higher age (P < 0.001) but similar BMI
compared to non-osteoporotic controls. Comparison of
lipid profile in patients and controls shows that the TC lev-
els were higher in the osteoporosis group than the control
group (218.15 ± 48.94 mg/dL vs. 195.9 ± 31.9 mg/dL, P <
0.001). Moreover, the LDL level of the osteoporosis group
was higher than that of the control group (122.15 ± 22.16
mg/dL vs. 104.2± 31.9 mg/dL, P < 0.001). The TG levels were
not significantly different between the groups (osteoporo-
sis group: 105.26± 18.25mg/dL, control group: 116.3± 45.5
mg/dL, P = 0.02). Similarly, the HDL levels were not signif-
icantly different between the groups (osteoporosis group:
46.5±6.9 mg/dL, control group: 49.3± 8.6 mg/dL, P = 0.01)
(Table 1).
The genotype distribution of the His 447 His polymor-
phism of PPARγ gene in both groups was in the Hardy-
Weinberg equilibrium (both P > 0.05). The distribution
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Table 1. Metabolic Parameters of Patients with Osteoporosis Versus Controlsa
Controls (n = 117) Patients (n = 107) P Value
Age (years) 55.73 + 2.08 61.03 + 4.54 < 0.001
BMI (kg/m2) 27.94 + 3.2 28.13 + 2.58 0.64
BMD-F -0.25 + 0.83 -2.29 + 0.82 < 0.001
BMD-S -0.45 + 0.72 -2.79 + 0.66 < 0.001
Ca (mg/dL) 9.4 + 0.48 9.44 + 0.54 0.69
VitD (nmol/L) 35.2 + 10.9 37.2 + 10.3 0.169
Triglyceride (mg/dL) 116.3 + 45.5 105.26 + 18.25 0.02
Cholesterol (mg/dL) 195.9 + 31.9 218.15 + 48.94 < 0.001
LDL-C (mg/dL) 104.2 + 31.9 122.15 + 22.16 < 0.001
HDL-C (mg/dL) 49.3 + 8.6 46.5 + 6.9 0.01
a Values indicate Mean± Standard deviation.
of genotypes was not different between the osteoporosis
group and the control group (79.4% CC, 16.8% CT, 3.7% TT
vs. 79.5%, 18.8%, 1.7%, respectively, P = 0.6) (Table 2).
The risk of osteoporosis in different genetic groups was
calculated by logistic regression analysis (Table 3).
This analysis showed no statistically significant differ-
ence between the groups in the risk of endometriosis (P =
0.99, odds ratio [OR] = 0.995, 95% confidence interval [CI]
= 0.47 - 2.09) after adjustment for TC and LDL-C. ANOVA
test also showed no statistically significant difference in
metabolic parameters in the study women (Table 4). There
was no difference even when the control and osteoporosis
groups were analyzed separately.
4. Discussion
Peroxisome proliferator-activated receptor gamma
(PPAR-γ) is an essential cellular factor for the control over
a number of physiological processes and pathogenesis
of various diseases. PPAR-γ is an important transcription
factor in adipocyte differentiation that seems to have an
important role in bone metabolism. Recent studies have
shown that PPAR-γ not only suppresses osteoblast forma-
tion, but also plays a vital role in osteoclastogenesis and
bone resorption with the help of PPAR-γ coactivator 1β
(PGC1β) and estrogen-related receptor alpha (ERR α) (18).
In addition, numerous studies have discussed the role of
various PPAR-γ gene polymorphisms on lipid metabolism
as well as bone turnover (13, 14, 17, 19, 20). Therefore, the
aim of this study was to evaluate the effects of polymor-
phisms in the PPAR-γ gene on bone mineral density (BMD)
and lipid profile of postmenopausal women with or with-
out osteoporosis. Our findings suggested no association
of different types of PPAR-γ gene polymorphism with
BMD. This finding is consistent with those of Yu et al. study
conducted among Chinese women (13).
However, the results of many studies indicate the rela-
tionship between PPAR-γ gene polymorphisms and BMD
(20). Surveys conducted in Korea and Japan have found
that C161T (His 447His) polymorphism is associated with
decreased levels of OPG and BMD, particularly prominent
among postmenopausal women (13, 14, 19). Rhee et al.
have also demonstrated that those with Pro2Ala polymor-
phisms in PPAR-γ gene have reduced OPG levels in their
serum (17). This discrepancy could be due to different eth-
nic background and sample size of this study with other
surveys, as Rooki et al. evaluation of C161T and Pro12Ala
polymorphisms of PPAR-γ gene among Iranian population
has shown that the prevalence of such disturbances is sig-
nificantly different from those of other investigated popu-
lations, including Korean population (21).
In addition, the results of this study supported that
bone density levels are inversely associated with serum
levels of LDL and total cholesterol, as postmenopausal
women with osteoporosis showed significant differences
in LDL and total cholesterol values. Other conducted stud-
ies also discovered evidence in favor of the correlation be-
tween BMD and serum lipid levels among postmenopausal
women (22). However, the serum lipid profile showed no
significant difference in all the 3 studied polymorphisms
of PPAR-γ gene. Zafarmand et al. have also demonstrated
that the PPAR-γ gene polymorphisms in healthy Dutch
women do not have a major impact on the average of lipid
profile (23).
Generally, the results of this study indicated that there
is no difference in the prevalence of PPAR-γ gene poly-
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Table 2. Genotype Distributions in Patients with Osteoporosis Versus Controlsa
Genotype Control Patients Total
CC 93 (79.5%) 85 (79.4%) 178 (79.5%)
CT 22 (18.8%) 18 (16.8%) 40 (17.9%)
TT 2 (1.7%) 4 (3.7%) 6 (2.7%)
117 107 224
a P Value = 0.60.
Table 3. Logistic Regression Analysis of Alleles with Respect to the Presence of Osteoporosis as Dependent Variablea
SNP Allele Compared to Non-Carries Univariate Multivariateb
OR 95 % CI P OR 95% CI P
His 447 His 0.997 0.52 - 1.91 0.99 0.995 0.47 - 2.09 0.99
a Values are 95% confidence interval (CI), odds ratio (OR). P value: chi-square test.
b Adjusted for TC and LDL-C.
Table 4. Metabolic Parameters According to the Genotypes
CC (n = 178) CT (n = 40) TT (n = 6) P Value
Age (years) 58.2± 4.2 58.4± 5.1 56.8± 3.3 0.70
BMI (kg/m2) 27.9± 2.9 28.4± 2.7 28.3± 1.3 0.52
BMD-F -1.19± 1.3 -1.2± 1.1 -2.1± 2.1 0.24
BMD-S -1.5± 1.3 -1.6± 1.2 -1.7± 1.8 0.91
Ca (mg/dL) 9.4± 0.7 9.4± 0.5 9.4± 0.4 0.95
Vit D (nmol/L) 36± 1 35.2± 9.5 45± 9.1 0.11
Triglyceride (mg/dL) 111.6± 36 110.4± 32 96.6± 8 0.59
Cholesterol (mg/dL) 207.5± 44 199.2± 35 224.3± 28 0.31
LDL-C (mg/dL) 113± 20 111± 17 116± 16 0.79
HDL-C (mg/dL) 48± 8 47± 8 47± 8 0.88
morphisms among postmenopausal women with or with-
out osteoporosis. The study also showed no significant
changes in LDL and total cholesterol levels in individu-
als with different polymorphisms of PPAR-γ gene. To our
knowledge, this is the first study that evaluated the poly-
morphisms of PPAR-γ gene in postmenopausal women
with osteoporosis. Lack of estrogen level assessment as an
intervening variable in bone and lipids metabolisms was
the limitation of our study.
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